RoTecPSMA^® Approved in Switzerland – Expanding Access to Advanced Prostate Cancer Diagnostics

We are delighted to announce that RoTecPSMA^® has received marketing authorization in Switzerland, marking another important milestone in the European rollout of this innovative diagnostic solution. This approval, achieved in close collaboration with our trusted partner and marketing authorization holder medeo AG, paves the way for Swiss patients to benefit from our PSMA SPECT tracer.

RoTecPSMA^® is a technetium-99m cold kit for SPECT imaging of prostate cancer patients and represents the first PSMA SPECT tracer approved in a European country. With its authorization, we continue to address critical gaps in patient care by offering a widely accessible and reliable diagnostic radiopharmaceutical.

This milestone reflects our strong commitment to enhancing diagnostic precision and improving quality of life for patients through theranostics. By expanding access to advanced diagnostic imaging solutions, we aim to ensure that more men living with prostate cancer can receive timely and precise assessments, ultimately enabling more informed and effective treatment decisions.

With approval granted, we are now moving forward with medeo AG to prepare for the market launch of RoTecPSMA^® in Switzerland. While some steps are still required, we are progressing toward making RoTecPSMA^® available to Swiss healthcare providers. Based on current planning, we anticipate broad availability could begin in the second quarter of 2026.

The Swiss approval also highlights the importance of strategic partnerships. Our collaboration with medeo AG ensures not only efficient distribution but also the local expertise required to successfully integrate RoTecPSMA^® into the Swiss healthcare system, providing physicians with a powerful tool in the fight against prostate cancer.

We look forward to seeing the positive impact RoTecPSMA^® will have on patient care in Switzerland and to continuing our mission of bringing innovative nuclear medicine solutions to healthcare professionals and patients worldwide.

Fore more information contact our Customer Service Team: customer.service@rotop-pharmaka.com